Syndax Pharmaceuticals Inc (SNDX)

18.72
0.10 0.53
NASDAQ
Prev Close 18.82
Open 18.84
Day Low/High 18.35 / 18.84
52 Wk Low/High 13.02 / 27.85
Volume 25.53K
Exchange NASDAQ
Shares Outstanding 48.63B
Market Cap 903.01M
P/E Ratio N/A
Div & Yield N.A. (N.A)
You've Got Volatility 'Covered' With This Strategy

You've Got Volatility 'Covered' With This Strategy

This simple option strategy, which I continue to use with small-cap biotechs, is one of the easiest and cheapest risk mitigation approaches an individual can take.

Here's a Quartet of Small Biotechs That Could Make for Acquisition Targets

Here's a Quartet of Small Biotechs That Could Make for Acquisition Targets

Merger activity is picking up this week in the biotechnology sector and these four promising companies would be good buyout candidates.

A Trio of Small Biotech Companies Garnering Attention

A Trio of Small Biotech Companies Garnering Attention

The three either have made recent progress toward advancing products in their pipelines or have caught the eye of analysts.

3 Small Biotech Stocks to Watch in the Fourth Quarter

3 Small Biotech Stocks to Watch in the Fourth Quarter

These are just a few of the names I expect to do well to close out 2018.

3 Small Biotechs on My Q4 Watch List

3 Small Biotechs on My Q4 Watch List

These are a few of the names I expect to do well to close out 2018.

2 Stealthy Moves in Biotech

Market ends flat to close the trading week even as the S&P 500 closes out its best quarter since 2013. A couple of small biotechs made some stealth moves up this week in including Syndax Pharmaceuticals , which broke through resistance. Also, Therav...

How I See Biotechs Now

How I See Biotechs Now

I expect deal volume to have a substantial uptick before the end of 2018 rolls around.

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

4 Names to Watch Ahead of This Year's Key Cancer-Research Conference

These names are moving up or down in a big way ahead of releasing drug-trial results.

This Market Is One Bad Headline Away From a Buyable Dip

This Market Is One Bad Headline Away From a Buyable Dip

Speculative action is keeping sentiment from being more negative.

These 2 Biotech Stocks Still Have Upside

These 2 Biotech Stocks Still Have Upside

The biotech sector has seen a big rally, but there are still opportunities.

Mid-Afternoon Update

2:15 pm update Markets are pretty much where they were 90 minutes ago. The S&P has strengthened a bit and overall equities have held up better than I thought given the potential partial government shutdown this weekend. We will see if stocks hold th...